Intralesional Versus Perilesional 5% Dextrose Injection in Partial Rotator Cuff Tears
RecruitingNot applicableNCT07688902
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This prospective, randomized, double-blind controlled clinical trial aims to compare the clinical and ultrasonographic outcomes of intralesional and perilesional 5% dextrose injection in patients with partial rotator cuff tears. Eligible participants will be randomized into two parallel groups. Both groups will receive ultrasound-guided 5% dextrose injection to the supraspinatus enthesis. In addition, one group will receive intralesional 5% dextrose injection, while the other group will receive perilesional 5% dextrose injection using the peppering technique. Injections will be performed in three treatment sessions at 21-day intervals. All participants will receive a home-based exercise program after completion of the injection treatments. Clinical outcomes will be assessed at baseline, 9 weeks, and 12 weeks after treatment, and ultrasonographic outcomes will be assessed at baseline and 12 weeks.
Study details
- Official title
- Comparison of Clinical and Ultrasonographic Outcomes of Intralesional and Perilesional 5% Dextrose Injection in Patients With Partial Rotator Cuff Tears: A Prospective Randomized Double-Blind Controlled Trial
- Conditions
- Partial Rotator Cuff Tears
- Rotator Cuff Tendinopathy
- Shoulder Pain Chronic
- Supraspinatus Tendon Tear
- Interventions
- Procedure: Intralesional 5% Dextrose Injection
- Procedure: Perilesional 5% Dextrose Injection
- Sponsor
- Ankara City Hospital Bilkent
- Start date
- 2025-02-01
- Primary completion
- 2026-10-01
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- Turkey (Türkiye)
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Diagnosis of partial rotator cuff tear by a specialist physician after appropriate clinical examination and imaging evaluation * Shoulder pain and functional limitation lasting for at least 3 months * Clinically confirmed shoulder impingement findings, defined as at least one positive test among Neer, Hawkins-Kennedy, or painful arc tests * Age between 18 and 75 years * Ability to comply with the study procedures and attend follow-up visits regularly * Willingness to participate in the study and provide written informed consent Exclusion Criteria: * Advanced cognitive impairment or dementia preventing reliable completion of questionnaires * Refusal to participate in the study or inability to provide informed consent * Full-thickness rotator cuff tear * Major tendon pathology other than the supraspinatus tendon, such as full-thickness subscapularis tear or biceps tendon rupture * Advanced acromioclavicular joint osteoarthritis, marked impingement, or marked adhesive capsulitis * Advanced glenohumeral joint arthritis * Active infection, cellulitis, or dermatologic lesion at the injection site * Bleeding diathesis or anticoagulant use * Known allergy or intolerance to dextrose injection * Intra-articular shoulder injection, including steroid, platelet-rich plasma, or prolotherapy, within the last 3 months * Previous shoulder surgery * Uncontrolled diabetes mellitus, defined as HbA1c \>8.5%, or severe endocrine or metabolic disorder * Immunosuppression or active infection * Rheumatologic shoulder involvement * Neurological disease affecting shoulder movements * Pregnancy * Active malignancy
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07688902